Publications Database

Aman M. G. et al. (2014)

A review of atomoxetine effects in young people with developmental disabilities.

Research in Developmental Disabilities

June, 35(6), pp. 1412-1424.

Read Full (New Window)

Aman M. G. et al. (2005)

Acute and long-term safety and tolerability of risperidone in children with autism.

Journal of Child and Adolescent Psychopharmacology

15(6), pp. 869-884

Read Abstract (New Window)

Aman M. G. et al. (2008)

Cognitive effects of risperidone in children with autism and irritable behavior.

Journal of Child and Adolescent Psychopharmacology

18(3), pp. 227-236

Read Abstract (New Window) Read Full (New Window)

Aman M. G. et al. (2010)

Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder.

Journal of Child and Adolescent Psychopharmacology

20(5), pp. 415-422.

Read Abstract (New Window)

Aman M. G. (2004)

Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder.

Seminars in Pediatric Neurology

11(3), pp. 225-228

Read Abstract (New Window)

Aman M. G. et al. (2009)

Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial.

Journal of the American Academy of Child and Adolescent Psychiatry

48(12), pp. 1143-1154

Read Abstract (New Window) Read Full (New Window)

Aman M. G. , Turbott S. H. (1991)

Prediction of clinical response in children taking methylphenidate.

Journal of Autism and Developmental Disorders

21(2), pp. 211–228.

Read Abstract (New Window)

Aman M. G. et al. (1986)

Preliminary study of imipramine in profoundly retarded residents.

Journal of Autism and Developmental Disorders

16(3), pp. 263-273.

Read Abstract (New Window)

Aman M. G. et al. (1995)

Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use.

Journal of the American Academy of Child and Adolescent Psychiatry

34(12), pp. 1672-1681

Read Abstract (New Window)

Aman M. G. et al. (2017)

Safety and efficacy of memantine in children with autism: Randomized, placebo-controlled study and open-label extension.

Journal of Child and Adolescent Psychopharmacology

June, 27(5), pp. 403-412.

Read Abstract (New Window) Read Full (New Window)

Aman M. G. (1982)

Stimulant drug effects in developmental disorders and hyperactivity: toward a resolution of disparate findings.

Journal of Autism and Developmental Disorders

12(4), pp. 385-398

Read Abstract (New Window)

Aman M. G. (1996)

Stimulant drugs in the developmental disabilities revisited.

Journal of Developmental and Physical Disabilities

8(4), pp. 347-365

Read Abstract (New Window)

Aman M. G. et al. (1985)

The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects.

American Journal of Mental Deficiency

89(5), pp. 485-491

Read Abstract (New Window)

Aman M. G. et al. (2015)

Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial.

Journal of Child and Adolescent Psychopharmacology

August, 25(6), pp. 482-493.

Read Abstract (New Window) Read Full (New Window)

Aman M. G. , Hollway J. A. , Arnold L. E. (2008)

Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.

Child and Adolescent Psychiatric Clinics of North America

17(4), pp. 713-738

Read Abstract (New Window)

Aman M. G. (2005)

Treatment planning for patients with autism spectrum disorders.

Journal of Clinical Psychiatry

66 pp. 38-45

Read Abstract (New Window)

Anagnostou E. et al.

Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: A randomized clinical trial.

JAMA Psychiatry

Read Abstract (New Window)

Anderson G. M. et al. (2007)

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.

February, 61(4), pp. 545-550.

Read Abstract (New Window)

Arnold L. E. et al.

A 1.5-year follow-up of parent training and atomoxetine for attention-deficit hyperactivity disorder symptoms and noncompliant-disruptive behavior in autism.

Journal of Child and Adolescent Psychopharmacology

Read Abstract (New Window)

Arnold L. E. et al. (2000)

Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network.

Journal of Autism and Developmental Disorders

April, 30(2), pp. 99–111

Read Abstract (New Window)